The mosaic of laws that govern CBD legality across the globe varies just as much as the legislation across the US. Generally, CBD extract is legal in most countries, but what makes it illegal is where and what it’s extracted from. Most Group of 20 (G20) countries allow CBD extracted from industrial hemp, but not CBD extracted from whole-plant marijuana. Note, however, the differences between the two. Legislation regarding international travel with CBD also varies among countries. For the foreseeable future, the best practice would be to search online, or contact the respective embassies or consulates, before traveling to determine whether your CBD is safe and legal.
So is CBD legal? If we’re talking about hemp-derived CBD, then the answer is yes. Now, the keyword here is “hemp-derived.” Because CBD from hemp has no psychoactive effects, the purchase, sales, or possession of hemp CBD products are completely legal in all 50 States. Because hemp is sometimes confused with the marijuana plant, there is still some stigma towards hemp-derived CBD, but from a legal perspective, hemp-derived CBD is completely legal and enjoys the rights of any other legal product.
Perhaps the biggest concern for anybody with a job or kids or other responsibilities is whether CBD will induce psychoactive effects. While it’s true that CBD comes from cannabis plants, it does not cause any high. The two main compounds in cannabis are CBD and THC; and they are completely different in the effects they generate in the body. THC makes you high, but CBD stabilizes cognitive and neurological functions.
One classic use is in soaps. Hemp oil is also used in paints and lubricants, and as a body care product. It may be rubbed directly onto the skin to treat cracked, dry skin, or it can be blended into body oils, body creams, and other personal care products. Some people also use it as a dietary supplement, taking advantage of the high concentrations of essential fatty acids in unrefined hemp oil and using the oil as a dressing or garnish to improve nutrition.
In 1976, Canadian botanist Ernest Small and American taxonomist Arthur Cronquist published a taxonomic revision that recognizes a single species of Cannabis with two subspecies: C. sativa L. subsp. sativa, and C. sativa L. subsp. indica (Lam.) Small & Cronq. The authors hypothesized that the two subspecies diverged primarily as a result of human selection; C. sativa subsp. sativa was presumably selected for traits that enhance fiber or seed production, whereas C. sativa subsp. indica was primarily selected for drug production. Within these two subspecies, Small and Cronquist described C. sativa L. subsp. sativa var. spontanea Vav. as a wild or escaped variety of low-intoxicant Cannabis, and C. sativa subsp. indica var. kafiristanica (Vav.) Small & Cronq. as a wild or escaped variety of the high-intoxicant type. This classification was based on several factors including interfertility, chromosome uniformity, chemotype, and numerical analysis of phenotypic characters.
^ Russo, E. B.; Jiang, H.-E.; Li, X.; Sutton, A.; Carboni, A.; Del Bianco, F.; Mandolino, G.; Potter, D. J.; Zhao, Y.-X.; Bera, S.; Zhang, Y.-B.; Lü, E.-G.; Ferguson, D. K.; Hueber, F.; Zhao, L.-C.; Liu, C.-J.; Wang, Y.-F.; Li, C.-S. (2008). "Phytochemical and genetic analyses of ancient cannabis from Central Asia". Journal of Experimental Botany. 59 (15): 4171–82. doi:10.1093/jxb/ern260. PMC 2639026. PMID 19036842.
As a result of intensive selection in cultivation, Cannabis exhibits many sexual phenotypes that can be described in terms of the ratio of female to male flowers occurring in the individual, or typical in the cultivar. Dioecious varieties are preferred for drug production, where the female flowers are used. Dioecious varieties are also preferred for textile fiber production, whereas monoecious varieties are preferred for pulp and paper production. It has been suggested that the presence of monoecy can be used to differentiate licit crops of monoecious hemp from illicit drug crops. However, sativa strains often produce monoecious individuals, probably as a result of inbreeding.
Wikidata: Q79817 Wikispecies: Cannabis APDB: 189080 APNI: 106875 BioLib: 3465 EoL: 72695 EPPO: 1CNIG FloraBase: 22595 FNA: 105522 FoC: 105522 GBIF: 2984538 GRIN: 2034 iNaturalist: 72032 IPNI: 40737-1 IRMNG: 1280947 ITIS: 19108 NBN: NHMSYS0000456774 NCBI: 3482 NZOR: 5344e3b5-4049-474a-ac38-eb23ffc8f216 PLANTS: CANNA POWO: urn:lsid:ipni.org:names:30204649-2 Tropicos: 40000735 uBio: 4894539 VASCAN: 945
Our products include foods that are prepared in a way that safeguards their nutritional value. The majority of these ingredients are grown locally on our certified organic farm and may require chopping, dicing, juicing and/or drying for use in our products. The resulting whole food ingredients are then added to a formula that may include whole food extracts, animal tissue extracts and concentrates, botanicals, whole food isolates and synthetic ingredients. These highly complex combinations contain a variety of elements designed to trigger trophic effects that support the body’s healthy balance and wellness.*
Oral dronabinol (THC) is marketed in synthetic form as Marinol® (Solvay Pharmaceuticals) in various countries, and was approved in the USA for nausea associated with chemotherapy in 1985, and in 1992 for appetite stimulation in HIV/AIDS. Oral dronabinol’s expense, variability of action, and attendant intoxication and dysphoria have limited its adoption by clinicians (Calhoun et al 1998). Two open label studies in France of oral dronabinol for chronic neuropathic pain in 7 subjects (Clermont-Gnamien et al 2002) and 8 subjects (Attal et al 2004), respectively, failed to show significant benefit on pain or other parameters, and showed adverse event frequently requiring discontinuation with doses averaging 15–16.6 mg THC. Dronabinol did demonstrate positive results in a clinical trial of multiple sclerosis pain in two measures (Svendsen et al 2004), but negative results in post-operative pain (Buggy et al 2003) (Table 1). Another uncontrolled case report in three subjects noted relief of intractable pruritus associated with cholestatic jaundice employing oral dronabinol (Neff et al 2002). Some authors have noted patient preference for whole cannabis preparations over oral THC (Joy et al 1999), and the contribution of other components beyond THC to therapeutic benefits (McPartland and Russo 2001). Inhaled THC leads to peak plasma concentration within 3–10 minutes, followed by a rapid fall while levels of intoxication are still rising, and with systemic bioavailability of 10%–35% (Grotenhermen 2004). THC absorption orally is slow and erratic with peak serum levels in 45–120 minutes or longer. Systemic bioavailability is also quite low due to rapid hepatic metabolism on first pass to 11-hydroxy-THC. A rectal suppository of THC-hemisuccinate is under investigation (Broom et al 2001), as are transdermal delivery techniques (Challapalli and Stinchcomb 2002). The terminal half-life of THC is quite prolonged due to storage in body lipids (Grotenhermen 2004).
Some CBD oil brands can be evasive when it comes to product testing details. Populum addresses this by including a hard copy of the oil’s lab testing results in the product packaging. Full lab results are easily accessible on the brand’s website, as well. Prices for the Populum CBD oil range from 18 to 24 cents per milligram, depending on the container size, making it a relatively inexpensive full spectrum product. All U.S. military veterans receive a 25% discount, as well. Populum offers a risk-free 30-night product trial.
A study by Henquet and colleagues (2004) substantially replicated both the Swedish and Dutch studies in a 4-year follow-up of a cohort of 2437 adolescents and young adults between 1995 and 1999 in Munich. They found a dose–response relationship between self-reported cannabis use at baseline and the likelihood of reporting psychotic symptoms. As in the Dutch cohort, young people who reported psychotic symptoms at baseline were much more likely to experience psychotic symptoms at follow-up if they used cannabis than were cannabis-using peers without such a history.
Topicals represent a newer emerging market in medical marijuana products geared toward health and beauty. Cannabinoids can be absorbed through the skin for certain therapeutic benefits without any psychoactivity. Additionally, the essential oils in hemp and cannabis provide many benefits for skin health. From moisturizers to shampoos and deodorants, medical cannabis products continue to diversify.
As the PeaceHealth website suggests, hemp oil derives from a plant that contains high levels of the neurological chemical THC. This chemical can cause hallucinations, euphoria or high anxiety in supplement users when taken on a regular basis. As such, hemp oil supplements can cause similar effects in some patients using the herb for the treatment of any disorder. It is recommended that supplement users not take hemp oil products prior to operating machinery or driving due to the risk of these hallucinogenic properties. This is especially true to individuals who are overly-sensitive to THC, which can be determined by visiting your medical doctor for more information.
Cannabinoids may offer significant “side benefits” beyond analgesia. These include anti-emetic effects, well established with THC, but additionally demonstrated for CBD (Pertwee 2005), the ability of THC and CBD to produce apoptosis in malignant cells and inhibit cancer-induced angiogenesis (Kogan 2005; Ligresti et al 2006), as well as the neuroprotective antioxidant properties of the two substances (Hampson et al 1998), and improvements in symptomatic insomnia (Russo et al 2007).
What is CBD Pain Freeze? Hemp Bombs CBD Pain Freeze is a premium CBD topical infused with the soothing qualities of Menthol and Camphor Oil. It features the medicinal properties of CBD, or Cannabidiol, which may help relieve inflammation, reduce chronic pain and provide support to your bones, joints and muscles. CBD Pain Freeze is formulated to absorb deeply without leaving a sticky residue. This deep-penetrating CBD rub is a popular choice among athletes, senior ...
The clinical trials performed with Sativex have recently been assessed in two independent review articles (Barnes 2006; Pérez 2006). In a Phase II clinical trial in 20 patients with neurogenic symptoms (Wade et al 2003), Tetranabinex, Nabidiolex, and Sativex were tested in a double-blind RCT vs placebo (Table 1). Significant improvement was seen with both Tetranabinex and Sativex on pain (especially neuropathic), but post-hoc analysis showed symptom control was best with Sativex (p < 0.0001), with less intoxication than with THC-predominant extract.
Perhaps the most prevalent use for CBD is for pain management. The reality is that pain will affect everyone at some point in his or her life, and it’s comforting to know that there is a natural remedy that can help. The use of a natural remedy is especially important for those suffering from neuropathic pain and chronic pain – or pain that lasts for more than a few months. Chronic pain affects more than 3 million people in the United States every year – and the worst part? It can’t be cured. However, it can be treated and the irony is that in the United States, the most common medical treatments are nerve blocks, steroids, and narcotics (opioids) – many of which carry significant risk of side effects and addiction. Even over the counter non-steroidal anti-inflammatory drugs (NSAIDs) like Aspirin and ibuprofen are dangerous when used regularly – hospitalizing over 100,000 people each year and killing approximately 15,000. However, dangerous narcotics and NSAIDs are not your only option for pain relief! In addition to physical therapy and self-care, you can incorporate CBD into your treatment regimen for natural, plant-based pain relief. CBD is fundamentally different than most prescribed painkillers, as it’s not addictive, non-toxic, and has very minimal (if any) side effects.
It is hard to determine whether marijuana alone can cause cancer because many people who smoke marijuana also smoke cigarettes and use other drugs. Marijuana smoke contains some of the same cancer-causing compounds as tobacco, sometimes in higher concentrations. Studies show that someone who smokes five joints per day may be taking in as many cancer-causing chemicals as someone who smokes a full pack of cigarettes. Moreover, marijuana smokers usually inhale more deeply and hold their breath longer than tobacco smokers, which increases the lungs' exposure to carcinogenic smoke. Thus, puff for puff, smoking marijuana may increase the risk of cancer more than smoking tobacco does.
CBD does not appear to have any psychotropic ("high") effects such as those caused by ∆9-THC in marijuana, but may have anti-anxiety and anti-psychotic effects. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical marijuana" (with varying degrees of psychotropic effects and deficits in executive function) – from "medical CBD therapies” which would commonly present as having a reduced or non-psychoactive side-effect profile.
Researchers in New Zealand have studied whether cannabis can be used to treat severe motor and vocal tics in those suffering from Tourette syndrome. The study concluded that subjects who took a controlled THC-CBD medicated spray showed marked improvement in the frequency and severity of motor and vocal tics post-treatment. Although the study is only a small clinical trial, it is one of the first to specifically analyze the effects of cannabis on Tourette syndrome.
Medical cannabis (or medical marijuana) refers to the use of cannabis and its constituent cannabinoids, to treat disease or improve symptoms. Cannabis is used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, and to treat chronic pain and muscle spasms. Cannabinoids are under preliminary research for their potential to affect stroke.
Technically speaking, its THC—the cannabinoid that gets you high—which is illicit. When you take a drug test, the aim is to detect THC in your body, not “cannabis.” If you possessed weed without any THC in it, technically you wouldn’t be in violation of the law. Because “weed” without THC has a different name: hemp. And the rules governing hemp are quite different from the restrictions placed on cannabis.
Zammit and colleagues’ findings were supported in a 3-year longitudinal study of the relationship between self-reported cannabis use and psychosis in a community sample of 4848 people in the Netherlands (van Os et al., 2002). Van Os and colleagues reported that cannabis use at baseline predicted an increased risk of psychotic symptoms during the follow-up period in individuals who had not reported psychiatric symptoms at baseline. There was a dose–response relationship between frequency of cannabis use at baseline and risk of psychotic symptoms during the follow-up period. These relationships persisted when they statistically controlled for the effects of other drug use. The relationship between cannabis use and psychotic symptoms was also stronger for cases with more severe psychotic symptoms.
A. To date, the FDA has not approved a marketing application for marijuana for any indication. The FDA generally evaluates research conducted by manufacturers and other scientific investigators. Our role, as laid out in the Federal Food, Drug, and Cosmetic (FD&C) Act, is to review data submitted to the FDA in an application for approval to assure that the drug product meets the statutory standards for approval.
Whatever the reason behind the confusion stirred up by Mr. Curtis Hill in the November of 2017, it seems we can finally put it in the back burner. People who were using this as a health regiment for various ailments (especially the epileptic ones) shall continue to use it as a remedy. It is because there is no need to worry about any law restricting it.
In June 2018, the FDA approved the drug Epidiolex, an oral preparation of pure CBD for treatment of two rare and severe forms of epilepsy in children. The drug is made by the GW Pharmaceutical Company and was tested in three randomized, double-blind, placebo-controlled clinical trials, including 516 patients. It was found to be effective in reducing the frequency of seizures.
In 2014, the Kentucky legislature revised the definition of marijuana under state law to create legal protection for patients who use a cannabidiol (CBD) medicine as part of an approved clinical trial or on the written order of “a physician practicing at a hospital or associated clinic affiliated with a Kentucky public university having a college or school of medicine.”